Mode
Text Size
Log in / Sign up
N/A N=434 Randomized Prevention

1:1 Comparison of the Pocket Colposcope in Kenya

Cervical Cancer · HPV Infection · HIV Infections

Enrolled (actual)
434
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcome: Primary: Percent of Exams With Lesions Identified — 14.3; 17.3; 0; 21.1 percent of exams

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Pocket Colposcope (Device); Standard of Care Colposcopy (Procedure)
Age
Adult, Older Adult · 25+ yrs
Sex
Female
Sponsor
Duke University
Primary completion
May 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent of Exams With Lesions Identified
14.3; 17.3; 0; 21.1
PRIMARY
Sensitivity
26.3; 25.0
PRIMARY
Specificity
88.9; 84.0
PRIMARY
Negative Predictive Value (NPV)
82.9; 87.1
PRIMARY
Positive Predictive Value (PPV)
37.5; 20.6
SECONDARY
Percent of Participants Who Reported Having No Awareness About Cervical Cancer and Cervical Cancer Prevention, Assessed by Questionnaire
21.6; 21.8; 0.5; 0.5
SECONDARY
Percent of Providers Who Reported Experiencing no Challenges During the Exam
96.3; 97.0
SECONDARY
Percent of Participants Who Reported Experiencing Pain During Their Exam
21.6; 21.8; 73.2; 74.1; 5.3; 3.0
SECONDARY
Percent of Participants Who Expressed Confidence in Their Provider's Assessment
0.0; 0.0; 3.2; 2.5; 28.4; 28.4
SECONDARY
Percent of Participants Who Would Recommend the Exam to a Friend
0.0; 0.5; 1.1; 0.0; 22.6; 18.8

Summary

The Pocket colposcope has 510k FDA clearance and has been successfully used in almost 1500 unique patients globally in Duke and non-Duke protocols to date. 400 women who are HPV-positive and planned to undergo treatment at 6 Ministry of Health-supported outpatient clinics in Kisumu County will be recruited to the study. After providing informed consent, participants will be randomized 1:1 to either standard-of-care visual inspection or colposcopy with the Pocket Colposcope

Eligibility Criteria

Inclusion Criteria

  • Age > 25 years old and < 65 years old
  • Sex: Female
  • Positive HPV test within past 6 months
  • HIV+ women

Exclusion Criteria

  • Pregnant women (cannot perform a cervical biopsy on a patient who is pregnant unless absolutely indicated)
  • Women with a negative HPV test
  • Patients incapable of giving informed consent
  • Women with a history of cervical cancer
  • Pelvic exam concerning for cervical cancer or cervical infection
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04998318). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search